Rhythm Pharmaceuticals Inc RYTM

$86.44 -7.00 (-7.49%)

Valuation

Market cap
6,403,723,000
Revenue TTM
$189,760,000
Net income TTM
$-196,540,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-103.57%
Debt to equity
0.00

Trading

Volume
7,109,800
Avg volume
796,380
Day's range
$81.57 – $89.28
Shares out
68,533,000
Stochastic %K
35%
Beta
2.17
Analysts
Strong Buy
Price target
$141.33

Price

Company profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alst...

Show more

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 264 4280
Website
https://rhythmtx.com
Address
222 Berkeley Street, 12th Floor, Boston, United States

Latest news

Stocktwits

STUnusualVolume Nov 3, 8:15 PM
$RYTM is trading at 11.0x its normal volume for this time of day.
0 replies
Hognose Nov 3, 3:58 PM
$RYTM just another bearish stock
0 replies
abcdzepeda Nov 3, 3:56 PM
$RYTM
0 replies
prismmarketview Nov 3, 3:34 PM
$RYTM: LG Chem license amended + up to $750M loan → Royalty cut to 1% on global MC4R net sales (from low-to-mid-single digits), effective Jan. 1, 2029 or bivamelagon’s first sale → $350M fixed payments through Sept. 2029; new up-to-$200M milestone at $3B annual sales → Loan: $500M committed ($250M at ~Nov. 6 close), SOFR + 4.60%, 5 years, no equity component Caveats: debt, interest, and fixed payments. No new clinical data. $RYTM #Biotech https://prismmarketview.com/rhythm-revises-lg-chem-license-terms-secures-loan-facility-of-up-to-750-million/
0 replies
notreload_ai Nov 3, 3:13 PM
$TEVA +4.5%: Earnings beat, raised guidance for key drugs, new biosimilar deal. $SYY -4.5%: Sales miss, expects lower end of full-year sales growth. $RYTM -10%: Strong obesity drug sales, but $350M royalty payment spooked investors. https://notreload.xyz/wall-street-live-tuesday-november-3/
0 replies
SportTrade Nov 3, 3:02 PM
$PTN Strong Q3 beat for $RYTM ( the only commercially avail MC4R drug) and valued at ~$7BN mkt cap reinforces my conviction in upside for MC4R assets esp future prospects for next gen assets and the only other publicly listed co $PTN…icurrently trading at under $10M mkt cap…shocking! Interestingly, RYTM amended its biva (next gen oral) license with LG Chem agreeing to pay $350M in exchange for reducing the royalty to 1%, from low MSDs. That further reinforces IMO they have confidence in upside for next gen assets which bodes really well for PTN which preclinically may be even more competitive but will have to see in clinic. Yes there has been delays but new preclin data promising for their lipid (next gen asset) safety and potentially offer less than weekly dosing so fundamentals IMO totally disconnected from price. Get thru tax loss selling and remove funding overhang to recover. Im adding back once again this val’n makes zero sense with risk reward attractive. GLTA
0 replies
shoc24 Nov 3, 2:29 PM
$RYTM reported earnings this morning before the open and beat EPS estimates with a smaller loss: -$0.61 GAAP EPS vs -$0.7097 expected, according to Stock Meadow.
0 replies
EarningsInsider Nov 3, 2:17 PM
https://www.marketbeat.com/earnings/reports/2026-11-3-rhythm-pharmaceuticals-inc-stock/ $RYTM Rhythm Pharmaceuticals Earnings Transcript
0 replies